Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Kidney Neoplasms × palbociclib × Clear all

Phase

Status

Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 21 Neoplasms 6 Neoplasm Metastasis 5 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 Breast Diseases 2 von Hippel-Lindau Disease 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors Refractory to Standard Therapy 1 Solid Tumor, Adult 1 Solid Tumor 1 Sarcoma 1 Rare Tumor 1 Pancreatic Neoplasms 1 Neoplasms by Site 1 Neoplasm, Residual 1 Melanoma 1 Medulloblastoma 1 Malignant Female Reproductive System Neoplasm 1 Lung Neoplasms 1

Interventions

cabozantinib 7 pembrolizumab 6 Nivolumab 6 Ipilimumab 4 Axitinib 4 Radiosurgery 3 Blood Specimen Collection 3 zimberelimab 2 lenvatinib 2 Ultrasonography 2 Surveys and Questionnaires 2 Radiotherapy 2 Biopsy 2 tislelizumab 1 polyethylene glycol 3350 1 pazopanib 1 palbociclib 1 olaparib 1 gallium Ga 68 dotatate 1 cyclopropapyrroloindole 1 brodalumab 1 belzutifan 1 atezolizumab 1 anlotinib 1 adagrasib 1 Watchful Waiting 1 Vincristine 1 Therapeutics 1 Temozolomide 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07123090 2026-03-25

SPARCC

Dana-Farber Cancer Institute

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡